Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

Citation
Bilger, A., J. Plowshay, S. Ma, D. Nawand ar, E. A. Barlow, J. C. Romero-Masters, J. A. Bristol, et al. 2017. “Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication.” Oncotarget 8 (27): 44266-44280. doi:10.18632/oncotarget.17863. http://dx.doi.org/10.18632/oncotarget.17863.

Published Version
doi:10.18632/oncotarget.17863

Accessed
July 23, 2018 4:34:47 PM EDT

Citable Link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:34375187

Terms of Use
This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

(Article begins on next page)
Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication

Andrea Bilger1, Julie Plowshay2,6, Shidong Ma1,5, Dhananjay Nawandar3,7, Elizabeth A. Barlow1, James C. Romero-Masters4, Jillian A. Bristol1, Zhe Li8, Ming-Han Tsai8, Henri-Jacques Delecluse8 and Shannon C. Kenney1,2

1Department of Oncology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA
2Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA
3Department Cellular and Molecular Biology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, USA
4Department of Cellular and Molecular Pathology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA
5Sanofi Pharmaceuticals, Cambridge, Massachusetts, USA
6Rocky Mountain Infectious Disease Specialists, Aurora, Colorado, USA
7Department of Cancer Biology and Immunology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Cambridge, Massachusetts, USA
8Joint DKFZ Inserm Unit U1074, German Cancer Center (DKFZ), Heidelberg, Germany

Correspondence to: Shannon C. Kenney, email: skenney@wisc.edu

Keywords: therapy, lymphoma, lymphoproliferative disease, humanized mouse model, FDA-approved

Received: March 17, 2017 Accepted: April 27, 2017 Published: May 15, 2017

Copyright: Bilger et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

EBV infection causes mononucleosis and is associated with specific subsets of B cell lymphomas. Immunosuppressed patients such as organ transplant recipients are particularly susceptible to EBV-induced lymphoproliferative disease (LPD), which can be fatal. Leflunomide (a drug used to treat rheumatoid arthritis) and its active metabolite teriflunomide (used to treat multiple sclerosis) inhibit de novo pyrimidine synthesis by targeting the cellular dihydroorotate dehydrogenase, thereby decreasing T cell proliferation. Leflunomide also inhibits the replication of cytomegalovirus and BK virus via both “on target” and “off target” mechanisms and is increasingly used to treat these viruses in organ transplant recipients. However, whether leflunomide/teriflunomide block EBV replication or inhibit EBV-mediated B cell transformation is currently unknown. We show that teriflunomide inhibits cellular proliferation, and promotes apoptosis, in EBV-transformed B cells in vitro at a clinically relevant dose. In addition, teriflunomide prevents the development of EBV-induced lymphomas in both a humanized mouse model and a xenograft model. Furthermore, teriflunomide inhibits lytic EBV infection in vitro by preventing the initial steps of lytic viral reactivation, and by blocking lytic viral DNA replication. Leflunomide/teriflunomide might therefore be clinically useful for preventing EBV-induced LPD in patients who have high EBV loads yet require continued immunosuppression.
INTRODUCTION

Epstein-Barr virus (EBV) is a human herpesvirus that infects the majority of the world’s population and causes infectious mononucleosis [1]. Like all herpesviruses, EBV infects cells in both latent and lytic forms. EBV-infected humans sustain life-long latent viral infection within the memory B cell compartment, and periodically shed infectious viral particles into the saliva [2]. Once recovered from their initial infection, immunocompetent hosts only rarely develop symptomatic illness related to EBV. Nevertheless, EBV efficiently transforms primary B cells in vitro, and is associated with a variety of different types of B-cell lymphomas and EBV-induced lymphoproliferative disease (EBV-LPD) in humans, particularly in immunocompromised hosts [3].

Latent EBV infection is sufficient to transform B cells in vitro in the absence of any lytic viral gene expression [4], and the major EBV transforming proteins (EBNA2 and LMP1) are expressed during latent infection [3]. Nevertheless, both uncontrolled latent and lytic infection likely contribute to the development of EBV-LPD in immunosuppressed patients. Patients who require pharmacologic immunosuppression, such as bone marrow and solid organ transplant patients, have a high risk of developing EBV-LPD, particularly when they have high EBV loads in the blood [5]. High EBV loads in immunosuppressed patients are usually caused by a greatly increased number of latently-infected B cells; in some cases an increased number of lytically-infected cells also contribute to high viral load [6]. Drugs that can either prevent the proliferation of latently-infected B cells, and/or the production of infectious EBV particles, may help to prevent the development of EBV-LPD in immunosuppressed patients with high EBV loads. Valacyclovir, which inhibits viral replication when metabolized to acyclovir, has been shown to reduce the number of EBV-infected cells in healthy volunteers [7]. However, it remains controversial whether drugs that specifically inhibit lytic (but not latent) EBV infection effectively prevent and/or treat EBV-LPD in immunosuppressed patients [8–11].

Leflunomide, an immunosuppressive drug approved for the treatment of rheumatoid arthritis since 1998, is increasingly also used to treat human cytomegalovirus (HCMV) and BK virus infection in transplant patients [12–14]. Teriflunomide, the active metabolite of leflunomide, is approved for treatment of multiple sclerosis [15]. The “on target” effect of leflunomide and teriflunomide, which occurs at low doses, is mediated through inhibition of the cellular dihydroorotate dehydrogenase (DHODH) enzyme [16]. DHODH is required for de novo pyrimidine synthesis (but not for pyrimidine synthesis mediated by the salvage pathway), and “on target” effects of the leflunomide/teriflunomide are reversed in vitro by supplementing the media with uridine, which restores de novo pyrimidine synthesis. Lymphocytes are particularly dependent upon de novo pyrimidine synthesis for their proliferation [17], and the major “on target” immunosuppressive effect of leflunomide/teriflunomide is thought to be due to decreased T cell proliferation. In addition to decreasing the amount of pyrimidine-based nucleotides available for DNA/RNA synthesis, drugs that inhibit DHODH activity globally decrease the level of O-linked GlcNAcylate-modified proteins through an “on-target” effect [18]. Diffuse large B-cell lymphoma (DLBCL) cell lines and primary DLBCL tumor cells have higher levels of nuclear O-GlcNAcylate-modified proteins than do normal B-cells, and the levels of these proteins correlate with DLBCL cell growth and survival [19].

Higher doses of leflunomide (still easily achieved in patients) have been proposed to have numerous additional “off-target” effects in vitro [12, 20–23]. Inhibition of HCMV lytic replication by leflunomide is likely mediated through an “off target” effect, since it is not reversed by uridine supplementation, although the exact mechanism(s) by which the drug acts on HCMV replication are not clear [22, 24, 25]. Higher dose leflunomide has also been shown to inhibit the proliferation and survival of chronic lymphocytic leukemia (CLL) cells in vitro through “off-target” effects on signaling pathways such as NF-kappa B and STAT3 [23].

However, whether leflunomide or teriflunomide can be used to inhibit lytic viral replication in EBV-infected B cells (similar to its effect on HCMV), or to prevent proliferation and/or survival of latently infected B cells (similar to its effect on CLL cells), is not known. Here we have investigated whether therapeutically relevant levels of teriflunomide inhibit the lytic form of EBV replication and/or block proliferation of latently-infected B cells in vitro. In addition, we have used two different mouse models to ask if these drugs inhibit the growth of EBV-induced lymphomas in vivo at non-toxic doses. We show that teriflunomide not only blocks the lytic form of EBV infection (and hence could be used to prevent transmission of the virus from cell to cell), but also greatly decreases the growth of latently infected, EBV-induced lymphomas in vivo. These results suggest that leflunomide/teriflunomide may be useful for preventing (and potentially treating) EBV-induced LPD in immunosuppressed patients with high EBV loads.

RESULTS

Teriflunomide inhibits proliferation of EBV-transformed B cells in vitro

Leflunomide/teriflunomide inhibit the proliferation of T lymphocytes and can interfere with the replication of some viruses. We therefore examined whether the active leflunomide metabolite, teriflunomide (A771726), affects proliferation of EBV-transformed human B cells in vitro. As shown in Figure 1A and 1B, teriflunomide prevented proliferation of the EBV-transformed lymphoblastoid cell line (LCL), D4, in vitro; similar results were obtained with a second independently derived lymphoblastoid...
cell line, M81-Luc (data not shown). The addition of uridine to the media in cells treated with a very low dose of teriflunomide (10 μg/ml, which is well below the target plasma concentration of 40–80 μg/ml for treatment of rheumatoid arthritis patients) partially reversed this anti-proliferative effect (Figure 1B). At higher doses of drug (40 and 70 μg/ml) the anti-proliferative effect was not reversed by uridine. These results indicate that teriflunomide prevents proliferation of EBV-transformed human B cells through both “on target” and “off target” mechanisms. Importantly, since patients can tolerate a teriflunomide level as high as 100 μg/ml [26], high-dose leflunomide/teriflunomide could potentially be used to inhibit the proliferation of latently EBV-infected B cells in humans, thereby taking advantage of both the “on-target” and “off-target” effects of the drug.

Teriflunomide alters EBV latency protein expression in EBV-transformed B cells in vitro

To explore potential mechanisms(s) by which teriflunomide halts proliferation of EBV-transformed LCLs, we examined whether the drug alters expression of EBV latency proteins known to be required for LCL survival and proliferation in vitro. As shown in Figure 2A, teriflunomide treatment increased expression of two different EBV transforming proteins, EBNA2 (which mimics the effects of Notch signaling) [27] and LMP1 (which mimics the effects of CD40 signaling) [28], while not significantly affecting the expression of two other essential EBV transforming proteins (EBNA3A and EBNA3C). Furthermore, the ability of teriflunomide to increase EBNA2 and LMP1 expression was observed using a low dose (20 μg/ml) of drug and was reversed by uridine treatment, suggesting that it is due to an “on target” effect. The level of LMP1 transcript was also significantly higher in teriflunomide-treated versus untreated cells, and this effect was reversed by uridine treatment (Figure 2B). Interestingly, although low level LMP1 expression is required for proliferation and survival of EBV-transformed LCLs, higher level LMP1 expression (as little as twice that of normal level expression) inhibits B cell proliferation [29]. Taken together, these results suggest that excessive production of LMP1 may contribute to the anti-proliferative effect of teriflunomide in EBV-transformed LCLs.

Teriflunomide induces p53 expression and apoptosis in LCLs in vitro

We next determined whether teriflunomide’s effect on LCL growth is associated with increased apoptosis. The tumor suppressor protein, p53, plays a critical role in promoting both cell cycle arrest and apoptosis, and teriflunomide has been shown to increase p53 levels by blocking pyrimidine biosynthesis [30]. As shown in Figure 3A, teriflunomide treatment of LCLs increased p53 expression. Furthermore, teriflunomide treatment increased the level of cleaved PARP (a marker for apoptosis) [31], and the amount of activated caspases 3 and 7 (Figure 3B), and these effects were reversed by uridine supplementation. Thus, teriflunomide induces apoptosis of EBV-transformed B cells through its on-target mechanism, and this effect is likely at least partially mediated by increased p53 expression.

Teriflunomide does not inhibit canonical or non-canonical NF-κB signaling in EBV-transformed LCLs, and has little effect on c-Myc and cyclin E expression

Teriflunomide has been reported to induce killing of chronic lymphocytic leukemia (CLL) B cells in vitro
through off-target effects including suppression of the canonical NF-kB cell survival pathway [23]. Since EBV-transformed LCLs require LMP1-induced NF-kB for their survival [28], we examined whether teriflunomide inhibits the canonical or non-canonical NF-kB pathways in LCLs. As shown in Figure 3C, teriflunomide treatment did not reduce the level of phosphorylated p65 (a marker of canonical NF-kB signaling), or the amount of p52 produced by cleavage of p100 (a marker of the non-canonical NF-kB pathway; reviewed in [32]). Indeed,

Figure 2: Teriflunomide alters EBV latency protein expression in EBV-transformed B cells in vitro. (A) D4 LCLs were treated with teriflunomide or with DMSO control, each given alone or with 150 μM uridine. Cells were harvested after 7 days of treatment. Immunoblot analysis was performed using antibodies to the EBV latency proteins shown. β-actin was used as a loading control. (B) RNA was prepared from D4 LCLs treated with teriflunomide or DMSO control for 7 days, reverse-transcribed, and assessed using quantitative PCR with LMP1-specific primers. The level of LMP1 transcript in untreated cells is set as 1. The data represent one experiment done in duplicate.

Figure 3: Teriflunomide induces p53 expression and apoptosis in LCLs in vitro. D4 LCLs were treated with teriflunomide or with DMSO control, each given alone or with 150 μM uridine. Cells were harvested after 7 days of treatment (12 hours after the final drug treatment). (A) and (C) Immunoblot analysis was performed using antibodies to the cell survival and proliferation factors shown. β-actin was used as a loading control. (B) D4 LCLs were treated with teriflunomide or DMSO for 5 days. After one additional day of culture in the absence of drug, cells were assayed for caspase 3/7 activity using Caspase Glo (Promega).
the levels of these factors increased somewhat, likely reflecting the ability of increased LMP1 to induce both types of NF-κB pathways [28].

In addition, since EBNA2-induced c-Myc expression is required for LCL proliferation [33], we examined whether teriflunomide treatment reduces expression of either c-Myc, or its target gene, cyclin E [34], in LCLs. As shown in Figure 3C, there was no significant change in c-Myc or cyclin E levels in teriflunomide-treated cells. These results suggest that teriflunomide does not globally inhibit NF-κB survival pathways, or c-Myc-mediated transcription, in EBV-transformed B cells.

**Teriflunomide inhibits lytic EBV replication in B cells**

Given the ability of leflunomide to inhibit lytic HCMV replication [22, 24], we determined whether teriflunomide alters the amount of lytic EBV replication in EBV-infected B cell lines. Consistent with its ability to increase p53 expression, which has previously been shown to promote enhanced early lytic EBV protein expression [35, 36], teriflunomide increased levels of both the EBV immediate-early lytic protein, BZLF1, and the early lytic protein, BMRF1, in LCLs (Figure 4A). In spite of this activation of early lytic EBV proteins, the late viral capsid antigen, p18, was not expressed in teriflunomide-treated LCLs (Figure 4B). This result suggests that fully lytic EBV infection (required to transmit the virus from cell to cell) may be blocked by teriflunomide treatment.

We next examined the effect of teriflunomide treatment on lytic EBV protein expression and viral DNA replication in TGF beta-treated Burkitt lymphoma cells (Figure 4C). As previously described [36], TGF beta treatment of EBV-infected Burkitt cells activated expression of the EBV BZLF1 and BMRF1 immediate-early/early lytic proteins, as well as the EBV late lytic protein, p18. While low dose (20 μg/ml) teriflunomide treatment did not prevent TGF beta-mediated activation of early lytic EBV proteins, it blocked induction of the late EBV protein, p18 (Figure 4C), and this effect was largely reversed by uridine supplementation.

Since late EBV gene expression (but not early lytic gene expression) requires the lytic form of EBV DNA replication [37], we next asked whether teriflunomide decreases the amount of intracellular EBV DNA

---

**Figure 4: Teriflunomide inhibits lytic EBV replication in B cells.** Immunoblot analysis was performed to detect the immediate early lytic protein BZLF1, the early lytic protein BMRF1, or the late lytic protein p18 in control or teriflunomide-treated cells, with or without uridine supplementation. β-actin or GAPDH was used as a loading control. (A, B) D4 LCLs were treated with teriflunomide or with DMSO control, each given alone or with 150 μM uridine, for 7 days. The same extracts were used in panels A and B. Control HONE-Akata cells were treated for 3 days with 20 ng/ml TPA and 3 mM sodium butyrate, which are known to induce the late lytic EBV protein p18 in these cells. (C) Mutu I Burkitt cells were treated with teriflunomide or with DMSO control, given alone or with 150 μM uridine, for 3 days. TGFβ was given as indicated on day 0 to induce lytic activation. (D) DNA was extracted from untreated or TGFβ-treated Mutu I cells (treated with or without teriflunomide as indicated), and quantitative PCR was used to determine the amount of EBV DNA, normalized to the amount of β-globin DNA.
replication in TGFβ-treated Mutu I cells. As shown in Figure 4D, TGFβ treatment increased the amount of EBV DNA in Mutu I cells, and teriflunomide (even at the low dose, 20 μg/ml) prevented this. Together, these results reveal that teriflunomide inhibits the lytic form of EBV DNA replication in B cells at doses easily achieved in humans, and that this effect is at least partially mediated by its effect on de novo pyrimidine synthesis.

Teriflunomide inhibits the earliest step of lytic EBV reactivation in response to B-cell receptor ligation, or phorbol ester treatment

In the course of the TGFβ treatment studies, we discovered that teriflunomide prevents the ability of some lytic-inducing stimuli to activate a much earlier stage of lytic EBV reactivation (i.e., immediate-early BZLF1 protein expression). In particular, teriflunomide reduced immediate-early lytic protein BZLF1 and early lytic protein BMRF1 expression in response to B-cell receptor (BCR) ligation in both an EBV-transformed LCL line (Figure 5A) and an EBV-infected Burkitt line (Figure 5B). BCR stimulation by antigen is thought to be a biologically relevant mechanism by which the virus undergoes lytic reactivation in humans (reviewed in [35]). Low-dose teriflunomide also dramatically blocked BZLF1 and BMRF1 lytic protein expression in EBV-infected Burkitt cells treated with the combination of a phorbol ester (TPA) and an HDAC inhibitor (sodium butyrate; Figure 5C). Since the BMRF1 protein acts as the EBV DNA polymerase processivity factor, and is required for the lytic form of EBV DNA replication [38–40], no lytic EBV replication can occur in the absence of BMRF1 expression. Interestingly, teriflunomide blockade of early lytic EBV protein expression in response to TPA/sodium butyrate treatment and BCR stimulation was not reversed by uridine supplementation (Figure 5C and data not shown), although it occurred at low doses of the drug. Together, these results indicate the low dose teriflunomide inhibits the ability of EBV to lytically replicate its genome by multiple different mechanisms, some of which involve on-target effects, and others which are mediated through off-target effects.

Teriflunomide inhibits the growth of EBV-transformed LCLs in a xenograft mouse model

Given the ability of teriflunomide to inhibit proliferation of LCLs in vitro, we next asked whether teriflunomide treatment in vivo inhibits the growth

\[ \text{M81-Luc LCLs} \]

\[ \text{Mutu 1 BLs} \]

\[ \text{Kem I BLs} \]

Figure 5: Teriflunomide inhibits the earliest step of lytic EBV reactivation in response to B-cell receptor ligation or phorbol ester. Western analysis was performed to detect the immediate early lytic protein BZLF1 or the early lytic protein BMRF1 after lytic induction of control or teriflunomide-treated cells, with or without uridine supplementation. β-actin was used as a loading control. (A) M81-Luc LCLs were induced with a combination of 10 μg/ml anti-human IgG and 6.8 μg/ml anti-human IgM; (B) Mutu I Burkitt cells were induced with 10 μg/ml anti-human IgG; and (C) Kem I Burkitt cells were induced with a combination of 20 ng/ml TPA and 3 mM sodium butyrate.
of M81-Luc LCLs in a xenograft mouse model. For these experiments, we used an LCL transformed with an EBV virus (M81 strain) that contains a luciferase gene inserted into the viral genome under the control of the constitutively active HCMV IE gene promoter, such that optical scans could be used to measure tumor sizes at different time points. NSG mice were injected subcutaneously in each flank with 5 million M81-Luc LCL cells (mixed with matrigel), and then treated with teriflunomide (20 mg/ kg, three times a week), starting at day 8 after injection of the cells. The experiment was ended when untreated tumors reached the maximum allowable size for xenografts.

The amount of luciferase activity at each cell injection site was measured at several time points. As shown in Figure 6A and 6B, teriflunomide treatment dramatically reduced luciferase activity (a measurement of tumor size) relative to saline-treated animals, and did not cause any obvious toxicity in animals.

**Leflunomide prevents the development of EBV-induced lymphomas in a cord-blood humanized mouse model**

To further explore the potential utility of leflunomide/teriflunomide treatment for preventing EBV-induced lymphoproliferative disease in immunocompromised patients, we examined its effect in a recently developed cord-blood humanized mouse model. In this model, CD34-depleted cord blood cells are infected with EBV particles for 1 hour in vitro, and then cord blood cells are injected intraperitoneally into NSG mice. As previously described by our group [41], both EBV-infected B cells and human T cells engraft into the spleen and lymph nodes in this model. Human T cells initially act to inhibit the growth of EBV-induced B cell lymphomas in this system, even though most animals eventually die from such lymphomas [42]. If the ability of leflunomide/teriflunomide to prevent T cell proliferation is greater than its effect on EBV-induced lymphoma formation, then leflunomide could potentially promote lymphomas in this model via its on-target immunosuppressive effects on T cells.

In two independent experiments, mice treated with teriflunomide failed to develop lymphomas (Figure 7A). In the first experiment, teriflunomide treatment (20 mg/ kg, three times a week, starting at day 4 after injection of EBV-infected cord blood cells) prevented the development of EBV-induced lesions of any kind in the cord-blood humanized mouse model. Histological and immunohistochemical analysis of the lesions that developed in teriflunomide-treated animals in the second experiment revealed only non-invasive lymphoid aggregates (Figure 7B). The top panels of Figure 7B show a typical large lymphoma (invading the pancreas) from an untreated control animal; the bottom panels show the most advanced lesion we detected (an EBV-infected non-invasive lymphoid aggregate) among the teriflunomide-treated animals. As is typical of the EBV-induced large lymphomas that have overwhelmed the T cell immune response in this humanized mouse model, the untreated tumor was highly invasive and consisted almost exclusively of B cells (which express the CD20 antigen), and a small minority of T cells (which express the CD3 antigen; Figure 7C). Significantly, teriflunomide did not prevent T cells from interacting with the small cluster of EBV-infected B cells (Figure 7C). The B cells in both the teriflunomide-treated and untreated lesions were largely infected with EBV, as revealed by the presence of EBV-encoded small RNAs (EBERs) and expression of EBNA2 (Figure 7D). Furthermore, the dose of teriflunomide used (which resulted in a blood level of 40 μg/ml) did not

---

**Figure 6: Teriflunomide inhibits the growth of EBV-transformed LCLs in a xenograft mouse model.** NSG mice were injected subcutaneously in the flanks with 5 × 10^6 M81-Luc LCL cells on day 0, then treated with 20 mg/kg teriflunomide or PBS 3 times per week starting on day 8, and euthanized on day 21. (A) On days 8, 15, and 21, mice were given 150 mg/kg luciferin intraperitoneally and scanned using an IVIS imaging system. (B) The light produced during scanning was quantified using Living Image Software.
prevent engraftment of human T cells into the spleen of mice in this model (Figure 7E). These results indicate that teriflunomide treatment prevents EBV-infected B cells from forming invasive lymphomas in a humanized mouse model, where functional T cells have been shown to be required for control of EBV-induced lymphomas in the absence of teriflunomide treatment [42]. Thus, the T cell immunosuppressive effect of teriflunomide is counteracted by its growth inhibitory effect on EBV-infected B cells in this model.

DISCUSSION

Iatrogenic immunosuppression of transplant patients confers a greatly increased risk for EBV-induced LPD, which can be fatal. Development of LPD generally correlates with the overall degree of immunosuppression [43]. While reduction of immunosuppression can reverse EBV-induced LPD in many cases, it is not always feasible to reverse immunosuppression in patients who are also at high risk for organ rejection. Here we have investigated whether the immunosuppressive drug teriflunomide, a metabolite of leflunomide, prevents proliferation of EBV-transformed B cells in vitro and inhibits EBV-induced LPD in two different mouse models in vivo. We find that teriflunomide is surprisingly effective for inhibiting the growth of EBV-transformed B cells in vitro and treating EBV-induced lymphomas in vivo. In addition, we demonstrate that this drug prevents lytic EBV DNA replication in B cells both by blocking the ability of certain lytic inducing agents to activate expression of early lytic viral proteins, and by inhibiting lytic viral DNA replication. These results suggest that leflunomide/teriflunomide treatment of transplant recipients that have high EBV loads might reduce their risk of developing EBV-LPD. To our knowledge, this is the first demonstration that an immunosuppressive drug in clinical use can suppress EBV-LPD in vivo [43].

The inhibitory effect of teriflunomide on the proliferation and survival of EBV-infected LCLs in vitro appears to be multifactorial. At low doses, the effect is partially reversible by uridine supplementation and thus likely is due to the loss of activity of the major target of these drugs (cellular DHODH), and the resultant decrease in de novo pyrimidine synthesis. Previous studies have shown that rapid proliferation of activated lymphocytes in response to antigen stimulation requires de novo pyrimidine synthesis [17], and EBV-infected B cells hijack many of the same signaling pathways used by antigen-stimulated germinal center B cells to ensure their proliferation and survival [44]. In addition, consistent with a previous report showing that teriflunomide induces p53 activation [30], we found that low dose teriflunomide treatment of EBV-transformed LCLs increases p53 expression and apoptosis through an “on-target” mechanism.

Somewhat unexpectedly, we also discovered that teriflunomide greatly increases the amount of LMP1 expression in LCLs treated for one week. Importantly, although low level LMP1 expression is essential for proliferation and survival of established LCLs, higher level LMP1 expression, as found in teriflunomide treated LCLs, halts cell growth [45]. In addition, LMP1 over-expression in vivo may have an even more detrimental effect on LPD growth, as LMP1 increases T-cell mediated killing of EBV-infected B cells by enhancing MHC class I expression [46]. LMP1 expression is intricately regulated by the virus in LCLs through multiple different mechanisms. We found that teriflunomide increases both LMP1 RNA and protein levels. EBNA2, which we found at higher levels in teriflunomide-treated cells, as well as NFkB, which we also found to be elevated, are among the viral and cellular transcription factors that activate LMP1 transcription [47–49]. LMP1 is also regulated post-transcriptionally at the level of translation and autophagy-mediated degradation to ensure that levels of LMP1 are adequate to promote survival but not so high as to stop cell growth [29, 50, 51]. Although the exact mechanisms by which teriflunomide regulates LMP1 expression are not yet unraveled, the observed increase in LMP1 reflects an on-target effect (since it is reversible by uridine supplementation) and occurs at low doses of drug.

At higher doses in vitro (still clinically achievable in patients), we found that teriflunomide treatment produces an even more profound decrease in proliferation of EBV-transformed B cells, which is no longer reversed by uridine treatment. Thus these drugs also inhibit the proliferation of EBV-transformed B cells through “off-target” mechanisms. Although the precise mechanism(s) for these off-target effects on EBV-transformed B cells remain to be determined, they likely reflect the previously described ability of higher dose leflunomide/teriflunomide treatment to inhibit multiple different cellular tyrosine kinases, as well as AKT, S6 Kinase, NF-KB and STAT3 signaling [16, 23, 52]. Interestingly, however, we found increased, rather than decreased, NF-kappa B signaling in teriflunomide treated LCLs, presumably due to the increased expression of LMP1.

In addition, we show here for the first time that teriflunomide treatment blocks lytic EBV DNA replication in response to a variety of different lytic-inducing stimuli. While leflunomide has been previously reported to inhibit HCMV replication in vitro, the mechanism(s) by which it does so are not clear, and apparently occur downstream of intracellular viral DNA replication [22, 24]. Leflunomide/teriflunomide treatment also inhibits BK virus replication in newly infected cells; in this case, the drugs inhibit expression of the viral T antigen protein, which is required for viral replication [53]. A recent high-throughput screen for inhibitors of influenza virus replication identified a de novo pyrimidine synthesis inhibitor, A3, with effects on replication that were reversible by uridine [54]. A3 also
inhibited the replication of a number of other RNA and DNA viruses [54]. These results suggest that leflunomide/teriflunomide might have broad anti-viral activity by inhibiting viral replication through its effects on \textit{de novo} pyrimidine synthesis.

Interestingly, in the case of EBV, we found that teriflunomide can inhibit lytic EBV DNA replication through more than one mechanism, and through on-target and off-target effects. Teriflunomide blocks the ability of B-cell receptor stimulation, as well as TPA/sodium

![Figure 7: Teriflunomide prevents the development of EBV-induced lymphomas in a cord blood-humanized mouse model.](image)

In two independent experiments, NSG mice were injected with human cord blood infected with 2000 infectious units of the M81 EBV strain. Teriflunomide-treated animals received 20 mg/kg teriflunomide 3 times per week, starting on day 4. (A) Animals were euthanized after 28 days (first experiment; \( N = 4 \), each group) or 35 days (second experiment; \( N = 7 \), each group). Visible lesions were collected and analyzed histochemically. Lymphoma incidences for the two experiments were averaged. The significance of the difference in incidence between treated and untreated animals was calculated for each experiment; \( p \) values were then combined. (B–E) Histological analyses of a representative lymphoma from an untreated animal and the most advanced lesion found in a treated animal (both 28 days after infection). (B) Staining with hematoxylin and eosin (H&E) reveals that the lymphoma has invaded pancreatic tissue in the untreated animal. Images were taken with 2\( \times \) or 10\( \times \) objectives (20\( \times \) and 100\( \times \) magnification, respectively). (C) Antibodies to the B-cell marker CD20 and the T-cell marker CD3 reveal B cells and T cells in both the lymphoma and the lymphoid aggregate. (D) In situ hybridization for the EBV EBER RNAs and antibody staining for the EBV latency marker, EBNA2, reveal the presence of EBV-infected cells in both lesions. Immunohistochemical analysis of the spleen in (E) reveals the presence of T cells in both untreated and treated animals.
butyrate treatment, to induce even the very earliest step of
lytic EBV reactivation (expression of the viral immediate-
early lytic protein, BZLF1). While this effect occurs at low
doses, it is apparently due to an “off-target” effect since it
cannot be reversed by uridine.

In contrast, teriflunomide treatment does not
prevent the ability of TGFβ to activate expression of the
EBV immediate-early lytic protein, BZLF1, or the early
lytic EBV protein, BMRF1, but prevents its ability to
activate expression of a late structural protein (viral capsid
antigen p18). Furthermore, consistent with the known
inability of herpesvirus genes of the “late” class to be
transcribed in the absence of lytic viral DNA replication
[37], we found that the ability of TGF beta treatment to
induce intracellular EBV DNA replication is prevented by
teriflunomide. This latter effect appears to be at least
partially due to an on-target effect of the drug, since late
viral protein expression is partially rescued by uridine.

Perhaps the most striking finding in this study
is our demonstration that clinically relevant doses of
teriflunomide are quite effective for inhibiting the growth
of EBV-transformed B cells in two different mouse models
for EBV-LPD. In a cord-blood humanized mouse model
where EBV-infected B cells and human T cells are co-
egraft, teriflunomide treatment (starting 4 days after
injection of cells) did not prevent the engraftment of
EBV-infected B cells or human T cells, but did block the
ability of the EBV-infected B cells to form large invasive
lymphomas. This result is particularly notable, since we
have previously shown that human T cells inhibit the
growth of the EBV-infected B cells in this model. Thus,
the ability of teriflunomide to promote EBV-induced
lymphomas via a T cell immunosuppressive effect is
clearly outweighed by its ability to inhibit the proliferation
and/or survival of EBV-infected B cells.

In addition, in a xenograft model for EBV-LPD,
even when teriflunomide therapy was delayed until
8 days after LCL injection into mice (at which point small
tumors were already palpable, and could also be visualized
by luciferin scanning; Figure 6), the drug still greatly
inhibited the growth of the LCL-induced lymphomas. In
this xenograft model, only the ability of teriflunomide to
inhibit proliferation of latently-infected EBV-positive B
cells contributes to its anti-tumor effect, since EBV cannot
infect mouse cells, and all injected LCLs at the start of
the experiment were already EBV-infected.

In summary, our investigations here, using both
in vitro as well as in vivo systems to model the effects of
the FDA-approved leflunomide metabolite teriflunomide
on latent and lytic EBV B-cell infection, suggest that
these drugs may be surprisingly effective for treating
both latent and lytic EBV infection in humans. The most
obvious potential clinical use of leflunomide/teriflunomide
for control of EBV infection in humans would be in the
transplant recipient population, since such patients require
immunosuppression in any event, and are at high risk for
developing EBV-driven LPD. Nevertheless, these drugs
might also be useful in rare cases of fulminant infectious
mononucleosis, in which the clinical symptoms are due
not only to uncontrolled proliferation of virally-infected
B cells, but excessive T cell activation in response to
the EBV-infected B cells. In such cases, short term
leflunomide/teriflunomide therapy might not only reduce
clinical symptoms by inhibiting T cell proliferation, but
could also prevent the expansion of EBV-infected B cells.

A strength of our work is its demonstration that
teriflunomide inhibits spontaneous lymphomagenesis in
a human cord blood model of LPD. Limitations of our
studies include the examination of only one cell line
in xenografts, and the relatively short duration of the
teriflunomide treatment in both mouse models. Long-
term studies of the effect of leflunomide treatment on
LCL growth in our animal models would help determine
whether lymphomas become resistant to treatment. Finally,
clinical trials will be required to determine if leflunomide/
teriflunomide treatment is safe and effective, alone or in
combination with other immunosuppressive drugs, before
recommending such therapy for selected EBV-associated
diseases in humans.

MATERIALS AND METHODS

Cell lines and culture

Mutu I (a gift from Alan Rickinson) and Kem I
(a gift from Jeffrey Sample) are EBV-positive Burkitt
lymphoma cell lines and were cultured in RPMI (GIBCO)
supplemented with 10% FBS and 1% penicillin-
streptomycin. D4 LCL is an EBV-transformed (B95.8)
B cell lymphoblastoid cell line (LCL) derived from
the peripheral blood leukocytes of anonymous donors,
obtained from the American Red Cross [55]. M81-Luc
LCLs were obtained by infecting CD34-depleted human
cord blood (AllCells) with M81-Luc virus, described
below, and selecting immortalized cells. HONE-Akata (a
gift from Lawrence Young, University of Birmingham)
is an EBV-superinfected (Akata strain) epithelial cell
carcinoma cell line. These cells were grown in DMEM
(GIBCO) supplemented with 10% FBS (HyClone) and 1%
penicillin-streptomycin (GIBCO).

Construction of an M81 recombinant virus that
constitutively expresses the luciferase gene

We constructed a recombinant M81 strain with
constitutive luciferase activity (B1129) by introducing a
luciferase gene (pGL4.5, Promega) into the M81 BAC
[56] via homologous recombination [57] at the Smal
restriction site of the BXLF1 coding region (coordinate
131,127 on the M81 genome, GenBank accession number
KF373730.1). The expression of the luciferase gene on
this virus is driven by a CMV early enhancer/chicken beta
actin (CAG) promoter. The disruption of BXLF1 gene has previously been confirmed not to interfere with the growth of LCLs [58]. Infectious virions were harvested from 293 cells (ATCC) stably infected with M81-Luc virus.

In vitro drug treatment studies

Growth assays

D4 LCLs were plated at 2 × 10⁶ cells/ml on day 0 and harvested on day 7. One hour after plating, cells were treated with dimethyl sulfoxide control (DMSO; Sigma-Aldrich); or with 2.5 to 70 μg/ml teriflunomide (A771726; CalBiochem in Figure 1A; ENZO Life Sciences in all others) dissolved in DMSO. The final DMSO concentration in control and treatment groups was 0.1%. Uridine-treated cells were given 150 μM uridine one hour prior to teriflunomide or DMSO treatment. Growing cells were expanded into fresh medium containing DMSO or teriflunomide, with or without 150 μM uridine (Sigma-Aldrich), as needed. Cells treated with teriflunomide in Figure 1A were given fresh drug every 24 hours. Cells were counted using trypan blue exclusion (Figure 1A) or relative cell titers were determined using Cell Titer Glo as instructed by the manufacturer (Promega; Figure 1B).

Drug response studies

D4 LCLs were treated for 7 days with 6.5 to 70 μg/ml of teriflunomide, added one hour after cells were plated with or without uridine at 3 × 10⁶ cells/ml. Growing D4 LCLs were expanded into fresh medium supplemented with drugs as needed. All D4 LCLs were given fresh teriflunomide on day 3, day 5 (Figure 3C only), and day 6.5. M81-Luc LCLs, Mutu I, and Kem I cells at 2–5 × 10⁶ cells/ml on day 0 and were collected on day 7. One hour after plating, cells were treated with dimethyl sulfoxide control (DMSO; Sigma-Aldrich); or with 2.5 to 70 μg/ml teriflunomide (A771726; CalBiochem in Figure 1A; ENZO Life Sciences in all others) dissolved in DMSO. The final DMSO concentration in control and treatment groups was 0.1%. Uridine-treated cells were given 150 μM uridine one hour prior to teriflunomide or DMSO treatment. Growing cells were expanded into fresh medium containing DMSO or teriflunomide, with or without 150 μM uridine (Sigma-Aldrich), as needed. Cells treated with teriflunomide in Figure 1A were given fresh drug every 24 hours. Cells were counted using trypan blue exclusion (Figure 1A) or relative cell titers were determined using Cell Titer Glo as instructed by the manufacturer (Promega; Figure 1B).

Cell death assay

Cells were plated at 3 × 10⁵ cells/ml on day 0 and treated with teriflunomide or control DMSO. DMSO-treated wells required expansion on day 2. All cells received fresh drug/DMSO and medium on day 3. On day 5, cells were collected, washed twice with PBS, resuspended in fresh medium without drugs or DMSO, and plated at 3 × 10⁵ cells/ml. Caspase 3/7 activity was measured on day 6 using 25 μl sample and 25 μl Caspase Glo 3/7 (Promega).

Immunoblot analysis

Cell lysates were harvested in Sumo lysis buffer including protease inhibitors (Roche) as described previously [59], except cells were washed only once with PBS (DPBS, Gibco) prior to resuspension. Protein concentration was determined using the Sumo protein assay (Biorad), and proteins were separated in SDS-10% polyacrylamide gels and then transferred onto a nitro-cellulose membrane (0.22 μm, used only for p18, Maine manufacturing; or 0.45 μm, GVS North America). Membranes were blocked in PBS containing 5% non-fat dry milk (Roundy’s), and 0.1% Tween 20 (Sigma-Aldrich). Membranes were then incubated in PBS/5% Bovine Serum Albumin (Research Products International; for Exalpha antibodies), PBS/5%BSA/0.1% Tween 20 (Cell Signaling antibodies) or PBS/5%/milk/0.1% Tween 20 (all other antibodies). The following primary anti-human antibodies were used: anti-EBNA2 (mouse, #90543, clone PE2, Abcam, 1:500); anti-LMP1 (mouse, #78113, clones CS1-4, Abcam, 1:500); anti-EBNA3A (sheep polyclonal, Abcam, 1:2000); anti-EBNA3c (sheep polyclonal, Exalpha Pharmaceuticals, 1:2000); anti-β-actin (mouse, A5441, clone AC-15, Sigma, 1:5,000); anti-NFkB2p100/p52 (rabbit, #3017, Cell Signaling, 1:1000); anti-phosphoNFkBp65 (ser536, rabbit, #3303, clone 93H1, Cell Signaling 1:1000); anti-cMYC (rabbit, #32072, clone Y69, Abcam, 1:10,000); anti-Cyclin E (mouse, #sc-247, clone HE12, Santa Cruz, 1:250); anti-PARP (rabbit, #9542, Cell Signaling, 1:1000); anti-p53 (mouse, clone DO-1, Santa Cruz, 1:1000); anti-BZLF1 (mouse, sc-53904, B21, Santa Cruz, 1:500); anti-BMRF1 (mouse, MAB8186, clone R3, Millipore, 1:3000); anti-EBV p18 protein (goat polyclonal; Thermo Fisher Scientific, 1:2000); and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-horseradish peroxidase (HRP) antibody (A00192; Genscript; 1:4000). The secondary antibodies used were horseradish peroxidase (HRP)-labeled goat anti-mouse antibody (Thermo Fisher Scientific, 1:5000), goat anti-rabbit antibody (Thermo Fisher scientific, 1:5000); rabbit anti-sheep antibody (Santa Cruz, 1:5000); and donkey anti-goat antibody (Santa Cruz, 1:5000). Blots were developed with the Pierce ECL Western Blotting Kit (Thermo Fisher Scientific).

Reverse transcriptase quantitative PCR (RT-qPCR) analysis

Total RNA was extracted using the RNA-Bee reagent (Tel-Test Inc., catalog # Cs-104B) from D4 LCLs treated with 20 μg/ml teriflunomide or DMSO control for 7 days. The extracted RNA was then DNase treated, followed by reverse transcription using random primers and GoScript Reverse Transcriptase (Promega, catalog # A5000). Real-time PCR was performed on the reverse transcribed cDNA using the iTaq Universal SYBR Green mix (Bio-Rad, catalog
1.5 µl of cDNA was used for 40 cycles (15 seconds at 95°C and 30 seconds at 60°C), using primers that will detect LMP1 transcript originating from both TR and ED-L1 promoters (LMP1-TR + EDL1, forward primer: 5′- TGAGTAGGAGGGTGA – 3′ and reverse primer: 5′- CATATCTTGTCTCATGC - 3′) and beta-Actin transcript (forward primer: 5′ – GCC GGGACCTGACTGACTAC- 3′ and reverse primer: 5′- TTC TTCCTTAATGTCACGCACGAT– 3′). Beta-actin was used as a housekeeping gene, and transcripts were quantified using the delta-delta Cq methods for each time point.

**Viral DNA replication quantitative PCR assay**

Intracellular DNA from 10⁶ treated Mutu I cells (treatments as indicated in the Figure legend) was harvested, purified, and quantified as described [60].

**Mouse studies**

All animal experiments were approved by the University of Wisconsin-Madison Institutional Animal Care and Use Committee (IACUC) and conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals [61]. Immunodeficient NSG (NOD/LtSz-scid/IL2Rgnull) mice were bred at UW-Madison from stocks purchased from The Jackson Laboratory.

**Xenograft studies**

NSG mice were injected subcutaneously in the flanks with 5 × 10⁶ M81-Luciferase (M81-Luc) lymphoblastoid cells. Mice were treated with 20 mg/kg teriflunomide intraperitoneally three times a week, beginning on day 8 and sacrificed on day 21 post-infection (a total of six injections). To determine tumor size, mice were injected intraperitoneally with the luciferase substrate luciferin (150 mg/kg; Gold Biotechnology) and scanned using an IVIS Spectrum in vivo imaging system. The light produced by the luciferase was quantified using Living Image software (PerkinElmer).

**Production of infectious virus**

Infectious viral particles were produced from 293 cell lines stably infected with the M81 virus [56] or the M81-Luc virus following transfection with EBV BZLF1 and GP110 expression vectors as previously described [62]. EBV was titered on Raji cells (ATCC) using the Green Raji cell assay as previously described [62]. Images were taken with 2× and 10× objectives (20× and 100× magnification, respectively) using an Olympus BX53 microscope.

**Statistics**

Mstat Software (http://mcardle.wisc.edu/mstat/download/index.html) was used to statistically analyze the data. For tumor formation comparison, the p value was calculated using a two-tailed Fisher exact test.

**Ethics statement**

Investigation has been conducted in accordance with the ethical standards and according to the Declaration of Helsinki and according to national and international guidelines and has been approved by the authors’ institutional review board (UW SMPH ACUC protocol #5197).

**Authors’ contributions**

SCK, AB, JP, and SM designed research; AB, JP, SM, DN, EAB, JCR-M, JAB, ZL, and M-HT performed research; AB, ZL, M-HT, and H-JD contributed new reagents; and AB and SCK wrote the paper.

**ACKNOWLEDGMENTS**

We thank the Small Animal Imaging Facility, the Experimental Pathology Laboratory, and Lab Animal Resources staff at the Wisconsin Institutes for Medical Research for their excellent advice and assistance. We also thank Janet Mertz, Eric Johannsen, Paul Lambert and Bill Sugden for their advice on this project.
CONFLICTS OF INTEREST

The authors have no potential conflicts of interest.

FUNDING

This research was supported by grants P01CA22443 and R01CA174462 from the National Institutes of Health, and University of Wisconsin Cancer Center Support Grant P30 CA014520.

REFERENCES

1. Hjalgrim H, Friborg J, Melbye M. The epidemiology of EBV and its association with malignant disease. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007 [cited 2016 Dec 9]. Available from http://www.ncbi.nlm.nih.gov/books/NBK47424/

2. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000; 343:481–92. doi: 10.1056/NEJM200008173430707.

3. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004; 4:757–68. doi: 10.1038/nrc1452.

4. Feederle R, Kost M, Baumann M, Janz A, Drouet E, Hammerschmidt W, Delecluse HJ. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 2000; 19:3080–9. doi: 10.1093/emboj/19.12.3080.

5. Kamdar KY, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant. 2011; 16:274–80. doi: 10.1097/MOT.0b013e3283456715.

6. Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA. Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med. 1999; 199:567–76.

7. Hoshino Y, Katano H, Zou P, Hohman P, Marques A, Tying SK, Pollmann D, Cohen JL. Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers, J Virol. 2009; 83:11857–61. doi: 10.1128/JVI.01005-09.

8. McDiamid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, Martin MG, Bahar R, Maxfield AL, Ament ME, Busuttil RW, Lee GS. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation. 1998; 66:1604–11.

9. Hierro L, Diez-Dorado R, Díaz C, De la Vega A, Frauca E, Camarena C, Muñoz-Bartolo G, González de Zárate A, López Santamaría M, Jara P. Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus. Liver Transplant. 2008; 14:1185–93. doi: 10.1002/lt.21498.

10. Tse E, Kwong YL. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target. Exp Mol Med. 2015; 47: e136. doi: 10.1038/emm.2014.102.

11. AlDabbagh MA, Gitman MR, Kumar D, Humar A, Rotstein C, Husain S. The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review. Am J Transplant. 2016; 17:770–781. doi: 10.1111/ajt.14020.

12. Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet. 2002; 41:421–30. doi: 10.2165/00003088-200241060-00003.

13. Chacko B, John GT. Leflunomide for cytomegalovirus: bench to bedside. Transpl Infect Dis. 2012; 14:111–20. doi: 10.1111/j.1399-3062.2011.00682.x.

14. Jung YH, Moon KC, Ha JW, Kim SJ, Ha IS, Cheong HI, Kang HG. Leflunomide therapy for BK virus allograft nephropathy after pediatric kidney transplantation. Pediatr Transplant. 2013; 17: E50–54. doi: 10.1111/petr.12029.

15. He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L. Teriflunomide for multiple sclerosis. Cochrane Database Syst Rev. 2016; 3: CD009882. doi: 10.1002/14651858.CD009882.pub3.

16. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2000; 59:841–9.

17. Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem. 1995; 270:29682–9.

18. Sykes DB, Kfoury YS, Mercier FE, Wawer MJ, Law JM, Haynes MK, Lewis TA, Schajnovitz A, Jain E, Lee D, Meyer H, Pierce KA, Tolliday NJ, et al. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. Cell. 2016; 167:171–186.e15. doi: 10.1016/j.cell.2016.08.057.

19. Pham LV, Bryant JL, Mendez R, Chen J, Tamayo AT, Xu-Monette ZY, Young KH, Manyam GC, Yang D, Medeiros LJ, Ford RJ. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylgalcosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma. Oncotarget. 2016; 7:80599–80611. doi: 10.18632/oncotarget.12413.

20. Elder RT, Xu X, Williams JW, Gong H, Finnegar A, Chong AS. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol. 1997; 159:22–7.

21. Xu X, Shen J, Mall JW, Myers JA, Huang W, Blinder L, Saclarides TJ, Williams JW, Chong AS. In vitro and in vivo
antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action. Biochem Pharmacol. 1999; 58:1405–13.

22. Waldman WJ, Knight DA, Lurain NS, Miller DM, Sedmak DD, Williams JW, Chong AS. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation. 1999; 68:814–25.

23. Dietrich S, Krämer OH, Hahn E, Schäfer C, Giese T, Hess M, Tretter T, Rieger M, Hüllein J, Zenz T, Ho AD, Dreger P, Luft T. Leflunimide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells. Clin Cancer Res. 2012; 18:417–31. doi: 10.1186/1478-811X-8-31.

24. Waldman WJ, Knight DA, Blinder L, Shen J, Lurain NS, Miller DM, Sedmak DD, Williams JW, Chong AS. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology. 1999; 42:412–8.

25. Chong AS, Zeng H, Knight DA, Meister GT, Williams JW, Waldman WJ. Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am J Transplant. 2006; 6:69–75. doi: 10.1111/j.1600-6143.2005.01152.x.

26. van Roon EN, Jansen TL, van de Laar MA, Janssen M, Yska JP, Keuper R, Houtman PM, Brouwers JR. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: mechanisms of action. Biochem Pharmacol. 2002; 63:161–67. doi: 10.1016/S0006-2952(01)01827-7.

27. Gordadze AV, Peng R, Xu X, Jones R, Delecluse HJ, Zumwalde NA, Botz J, Wessbecher J, Draetta G, Eilers M. Differential modulation of cyclin gene expression by MYC. Proc Natl Acad Sci U S A. 1993; 90:3685–9.

28. Tsurumi T, Daikoku T, Kurachi R, Nishiyama Y. Functional interaction between Epstein-Barr virus DNA polymerase catalytic subunit and its accessory subunit in vitro. J Virol. 1993; 67:7648–53.

29. Neuhierl B, Delecluse HJ. The Epstein-Barr virus BMRF1 gene is essential for lytic virus replication. J Virol. 2006; 80:5078–81. doi: 10.1128/JVI.80.10.5078-5081.2006.

30. Murayama K, Nakayama S, Akasaka R, Ohbayashi N, Kamewari-Hayami Y, Terada T, Shirouzu M, Tsurumi T, Yokoyama S. Crystal structure of Epstein-barr virus DNA polymerase processivity factor BMRF1. J Biol Chem. 2009; 284:35896–905. doi: 10.1074/jbc.M109.051581.

31. Chaitanya GV, Steven AJ, Babu PP. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal CCS. 2010; 8: 31. doi: 10.1186/1478-811X-8-31.

32. Sun SC, Ley SC. New insights into NF-kappaB regulation and function. Trends Immunol. 2008; 29:469–78. doi: 10.1016/j.it.2008.07.003.

33. Zhao B, Zou J, Wang H, Johannsen E, Peng C, Quackenbush J, Mar JC, Morton CC, Freedman ML, Blacklow SC, Auster JC, Bernstein KE, Kieff E. Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth. Proc Natl Acad Sci U S A. 2011; 108:14902–7. doi: 10.1073/pnas.1108892108.

34. Jansen-Dürr P, Meichle A, Steiner P, Pagano M, Finke K, Botz J, Wessbecher J, Draetta G, Eilers M. Differential modulation of cyclin gene expression by MYC. Proc Natl Acad Sci U S A. 1993; 90:3685–9.

35. Kenney SC, Mertz JE. Regulation of the latent-lytic switch in Epstein-Barr virus. Semin Cancer Biol. 2014; 26:60–8. doi: 10.1016/j.semcancer.2014.01.002.

36. Fahmi H, Cochet C, Hmama Z, Opolon P, Joab I. Transforming growth factor beta 1 stimulates expression of the Epstein-Barr Virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway. J Virol. 2000; 74:5810–8.

37. Djavadian R, Chiu YF, Johannsen E. An Epstein-Barr Virus-Encoded Protein Complex Requires an Origin of Lytic Replication In Cis to Mediate Late Gene Transcription. PLoS Pathog. 2016; 12: e1005718. doi: 10.1371/journal.ppat.1005718.

38. Tsurumi T, Daikoku T, Kurachi R, Nishiyama Y. Functional interaction between Epstein-Barr virus DNA polymerase catalytic subunit and its accessory subunit in vitro. J Virol. 1993; 67:7648–53.

39. Neuhiel B, Delecluse HJ. The Epstein-Barr virus BMRFL1 gene is essential for lytic virus replication. J Virol. 2006; 80:5078–81. doi: 10.1128/JVI.80.10.5078-5081.2006.

40. Murayama K, Nakayama S, Akasaka R, Ohbayashi N, Kamewari-Hayami Y, Terada T, Shirouzu M, Tsurumi T, Yokoyama S. Crystal structure of Epstein-barr virus DNA polymerase processivity factor BMRF1. J Biol Chem. 2009; 284:35896–905. doi: 10.1074/jbc.M109.051581.

41. Ma SD, Xu X, Plowshay J, Ranheim EA, Burlingham WJ, Jensen JL, Asimakopoulos F, Tang W, Gulley ML, Cesarman E, Gumperz JE, Kenney SC. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis. J Clin Invest. 2015; 125:304–15. doi: 10.1172/JCI76357.

42. Ma SD, Xu X, Jones R, Delecluse HJ, Zumwalde NA, Sharma A, Gumperz JE, Kenney SC. PD-1/CyTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model. PLoS Pathog. 2016; 12: e1005642. doi: 10.1371/journal.ppat.1005642.

43. Lam GY, Halloran BP, Peters AC, Fedorak RN. Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders. World J Gastrointest Pathophysiol. 2015; 6:181–92. doi: 10.4291/wjgp.v6.i4.181.
44. Thorley-Lawson DA. EBV Persistence--Introducing the Virus. Curr Top Microbiol Immunol. 2015; 390:151–209. doi: 10.1007/978-3-319-22822-8_8.

45. Lam N, Sandberg ML, Sugden B. High physiological levels of LMP1 result in phosphorylation of elf2 alpha in Epstein-Barr virus-infected cells. J Virol. 2004; 78:1657–64.

46. Brooks JM, Lee SP, Leese AM, Thomas WA, Rowe M, Rickinson AB. Cyclical expression of EBV latent membrane protein 1 in EBV-transformed B cells underpins heterogeneity of epitope presentation and CD8+ T cell recognition. J Immunol. 2009; 182:1919–28. doi: 10.4049/jimmunol.0713607.

47. Fåhraeus R, Jansson A, Ricksten A, Sjöblom A, Rymo L. Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element. Proc Natl Acad Sci U S A. 1990; 87:7390–4.

48. Demetriades C, Mosialos G. The LMP1 promoter can be transactivated directly by NF-kappaB. J Virol. 2009; 83:5269–77. doi: 10.1128/JVI.00097-09.

49. Johansson P, Jansson A, Rüetschi U, Rymo L. Nuclear factor-kappaB binds to the Epstein-Barr Virus LMP1 promoter and upregulates its expression. J Virol. 2009; 83:1393–401. doi: 10.1128/JVI.01637-08.

50. Lee DY, Sugden B. The LMP1 oncogene of EBV activates PERK and the unfolded protein response to drive its own synthesis. Blood. 2008; 111:2280–9. doi: 10.1182/blood-2007-07-100032.

51. Lee DY, Sugden B. The latent membrane protein 1 oncogene modifies B-cell physiology by regulating autophagy. Oncogene. 2008; 27:2833–42. doi: 10.1038/sj.onc.1210946.

52. Doscas ME, Williamson AJ, Usha L, Bogachkov Y, Rao GS, Xiao F, Wang Y, Ruby C, Kaufman H, Zhou J, Williams JW, Li Y, Xu X. Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress. Neoplasia. 2014; 16:824–34. doi: 10.1016/j.neo.2014.08.006.

53. Liacini A, Seamone ME, Muruve DA, Tibbles LA. Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation. 2010; 90:1450–7. doi: 10.1097/TP0b013e3182007be2.

54. Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A. 2011; 108:5777–82. doi: 10.1073/pnas.1101143108.

55. Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, Kenney SC. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J Virol. 2005; 79:13993–4003. doi: 10.1128/JVI.79.22.13993-14003.2005.

56. Tsai MH, Raykova A, Kline O, Bernhardt K, Gartner K, Leung CS, Geletneyk Y, Sertel S, Münz C, Feederle R, Delecluse HJ. Spontaneous lytic replication and epitheliotropism define an Epstein-Barr Virus strain found in carcinomas. Cell Rep. 2013; 5:458–70. doi: 10.1016/j.celrep.2013.09.012.

57. Feederle R, Bartlett EJ, Delecluse HJ. Epstein-Barr virus genetics: talking about the BAC generation. Herpesviridae. 2010; 1: 6. doi: 10.1186/2042-4280-1-6.

58. Kanda T, Yajima M, Ahsan N, Tanaka M, Takada K. Production of high-titer Epstein-Barr virus recombinants derived from Akata cells by using a bacterial artificial chromosome system. J Virol. 2004; 78:7004–15. doi: 10.1128/JVI.78.13.7004-7015.2004.

59. Adamson AL, Kenney S. Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol. 2001; 75:2388–99. doi: 10.1128/JVI.75.5.2388-2399.2001.

60. Nawandar DM, Wang A, Makielski K, Lee D, Ma S, Barlow E, Reusch J, Jiang R, Wille CK, Greenspan D, Greenspan JS, Mertz JE, Hutt-Fletcher L, et al. Differentiation-Dependent KLF4 Expression Promotes Lytic Epstein-Barr Virus Infection in Epithelial Cells. PLoS Pathog. 2015; 11: e1005195. doi: 10.1371/journal.ppat.1005195.

61. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington (DC): National Academies Press (US); 2011 [cited 2016 Dec 9]. Available from http://www.ncbi.nlm.nih.gov/books/NBK54050/

62. Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y, Jankowska-Gan E, Burlingham WJ, Sun X, Gulley ML, Tang W, Gumperz JE, Kenney SC. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol. 2011; 85:165–77. doi: 10.1128/JVI.01512-10.